Why the study?
This study evaluated the real-world safety of sacubitril/valsartan for up to 52 weeks in Japanese patients with chronic heart failure.
Does sacubitril/valsartan have an acceptable safety profile in Japanese patients with chronic heart failure in a real-world setting?
Population
682 adult Japanese patients with chronic heart failure newly initiated on sacubitril/valsartan
Design
Uncontrolled, multicenter, observational study
Follow-up
Up to 52 weeks
Authors
Loading...
Supports real-world safety in Japanese HF; extends trial data without new signals but leaves generalizability open.
Does sacubitril/valsartan have an acceptable safety profile in Japanese patients with chronic heart failure in a real-world setting?
In a real-world Japanese cohort, sacubitril/valsartan demonstrated a safety profile consistent with known data, with hypotension being the most common adverse drug reaction.
Arita et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: